Ignite Creation Date:
2024-10-25 @ 8:03 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06600022
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-12
Brief Title:
Aims to Explore the Safety Tolerability and Preliminary Efficacy of SCTB41 in Adult Patients With Advanced Malignant Solid Tumours
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase III Open-label Multicentre Dose-escalation and Dose-expansion Study to Evaluate the Safety Pharmacokinetics and Anti-tumor Activity of SCTB41 in Patients With Advanced Malignant Solid Tumours
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to explore the safety tolerability PK characteristics immunogenicity and preliminary anti-tumor efficacy of SCTB41 as a monotherapy in adult patients with advanced malignant solid tumours This study is an open label multicentre dose-escalation and dose-expansion Phase III clinical trial
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None